GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » ROC (Joel Greenblatt) %

ACTU (Actuate Therapeutics) ROC (Joel Greenblatt) % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Actuate Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Actuate Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

ACTU's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -310.545
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Actuate Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Actuate Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Actuate Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics ROC (Joel Greenblatt) % Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
- - -

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Actuate Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Actuate Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actuate Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's ROC (Joel Greenblatt) % falls into.


;
;

Actuate Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.74) - (8.497 + 0 + 0)
=-7.757

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.566) - (7.914 + 0 + 0.889)
=-8.237

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Actuate Therapeutics for the quarter that ended in Dec. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-25.764/( ( (0 + max(-7.757, 0)) + (0 + max(-8.237, 0)) )/ 1 )
=-25.764/( ( 0 + 0 )/ 1 )
=-25.764/0
= %

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actuate Therapeutics  (NAS:ACTU) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Actuate Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Actuate Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Actuate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Actuate Therapeutics Headlines

From GuruFocus